Amneal Pharmaceuticals, Inc. (AMRX)
| Market Cap | 2.26B |
| Revenue (ttm) | 2.83B |
| Net Income (ttm) | -13.05M |
| Shares Out | 313.42M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | 10.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,034,729 |
| Open | 7.27 |
| Previous Close | 7.29 |
| Day's Range | 7.19 - 7.27 |
| 52-Week Range | 6.29 - 9.48 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 11.50 (+59.5%) |
| Earnings Date | May 2, 2025 |
About AMRX
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalm... [Read more]
Financial Performance
In 2024, Amneal Pharmaceuticals's revenue was $2.79 billion, an increase of 16.73% compared to the previous year's $2.39 billion. Losses were -$116.89 million, 39.2% more than in 2023.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for AMRX stock is "Strong Buy." The 12-month stock price forecast is $11.5, which is an increase of 59.50% from the latest price.
News
US FDA approves Amneal's migraine treatment
Amneal Pharmaceuticals said on Thursday the U.S. Food and Drug Administration has approved its self-administered migraine drug.
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate pati...
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal's extensive domestic pharmaceu...
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q1 2025 Earnings Call May 2, 2025 8:30 AM ET Company Participants Tony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Off...
Amneal Reports First Quarter 2025 Financial Results
BRIDGEWATER, N.J.--(BUSINESS WIRE)--AMNEAL REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS.
Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month.
Amneal to Report First Quarter 2025 Results on May 2, 2025
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report First Quarter 2025 Results on May 2, 2025.
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's Disease
BRIDGEWATER, N.J.--(BUSINESS WIRE)--New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® Extended-Release Capsules in Parkinson's Disease.
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson's Disease Patients in the U.S.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson's Disease Patients in the U.S.
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and Shilpa Medicare Limited (“Shilpa”) today announced ...
Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued
Amneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price apprecia...
Amneal to Participate at Upcoming Investor Conference
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Participate at Upcoming Investor Conference.
Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA.
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2024 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-C...
Amneal Reports Fourth Quarter and Full Year 2024 Financial Results
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Reports Fourth Quarter and Full Year 2024 Financial Results.
Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock
J.P. Morgan has upgraded Amneal Pharmaceuticals, Inc AMRX, noting the company's generics business is increasingly well-positioned with a solid Crexont launch and continued momentum across the portfoli...
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide.
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025.
Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved memantine/done...
Amneal to Participate at Upcoming Investor Conferences
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Participate at Upcoming Investor Conferences.
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist.
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President & Co-Chie...
Amneal Reports Third Quarter 2024 Financial Results
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Reports Third Quarter 2024 Financial Results.
Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets.
Amneal to Report Third Quarter 2024 Results on November 8, 2024
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report Third Quarter 2024 Results on November 8, 2024.